The study by the Veneto Institute of Oncology (IOV) in Padua, Italy, examined 286 patients for genomic mutations in cholangiocarcinoma as well as survival status. Cholangiocarcinoma, or bile duct ...
Bottom line: Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 ...
Bottom Line: Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 ...
The presence of FGFR2 alterations occurs almost exclusively in intrahepatic cholangiocarcinoma (iCCA) and is seen in 10% to 16% of patients. A question examined in abstracts over the past year has ...
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent type of pancreatic cancer, characterized as a highly lethal malignancy that is often preceded by precancerous lesions. These lesions are ...
Prospective study to assess taste related to eating disorders during chemotherapy using a dietary app: OISHY study. This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers ...
Aberrations in fibroblast growth factor receptors FGFR2/3 are major drivers of many cancers-including intrahepatic cholangiocarcinoma, endometrial, breast, gastric, and bladder cancers. However, the ...
Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database In this study, we performed anchored multiplex ...
The FDA’s Real Time Oncology Review (RTOR) pilot has inaugurated yet another new med. This time, the victory goes to a pair of Otsuka subsidiaries in a rare form of bile duct cancer. Late last week, ...
Notably, Insilico’s self-developed Chemistry42 played a crucial role in this research by generating the pyrrolopyrazine carboxamide core as a starting point for further molecular design. Moreover, ...
Fort Lee, N.J., March 30, 2026 (GLOBE NEWSWIRE)-- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results